 |
|
CLINICIAN'S CORNER
Scientific Rationale for a Change in the Composition of Oral Rehydration Solution
Christopher Duggan, MD, MPH;
Olivier Fontaine, MD;
Nathaniel F. Pierce, MD;
Roger I. Glass, MD, PhD;
Dilip Mahalanabis, MD;
Nur Haque Alam, MD;
Maharaj K. Bhan, MD;
Mathuram Santosham, MD, MPH
JAMA. 2004;291:2628-2631.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Diarrheal diseases remain important causes of death and morbidity in developing countries, with an estimated 1.5 billion episodes and 1.5 million to 2.5 million deaths each year among children younger than 5 years.1-4 Although the number of children currently dying from diarrhea continues to be unacceptably high, it is substantially lower than the 5 million deaths per year estimated 20 years ago.5
A critical factor in this reduction in diarrhea deaths has been the widespread adoption of oral rehydration solution (ORS) programs for the treatment and prevention of diarrhea-associated dehydration.6-7 Indeed, ORS has been hailed as one of the most important medical advances of the past century,8 at least in part because of its simplicity, low cost, . . . [Full Text of this Article] Advantages of Reduced-Osmolarity ORS
Author Affiliations: Division of Gastroenterology and Nutrition, Children's Hospital Boston, Boston, Mass (Dr Duggan); Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland (Dr Fontaine); Johns Hopkins Bloomberg School of Public Health, Baltimore, Md (Drs Pierce and Santosham); Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga (Dr Glass); Society for Applied Studies, Kolkata, India (Dr Mahalanabis); Clinical Sciences Division, ICDDR, B Centre for Health and Population Research, Dhaka, Bangladesh (Dr Alam); and Department of Pediatrics, All India Institute of Medical Sciences, New Delhi (Dr Bhan).
RELATED ARTICLE
Clinical Concerns About Reduced-Osmolarity Oral Rehydration Solution
David R. Nalin, Norbert Hirschhorn, William Greenough, III, George J. Fuchs, and Richard A. Cash
JAMA. 2004;291(21):2632-2635.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
MAPKAPK-2 Is a Critical Signaling Intermediate in NHE3 Activation Following Na+-Glucose Cotransport
Hu et al.
J. Biol. Chem. 2006;281:24247-24253.
ABSTRACT
| FULL TEXT
Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution.
Alam et al.
JAMA 2006;296:567-573.
ABSTRACT
| FULL TEXT
CFTR in cystic fibrosis and cholera: from membrane transport to clinical practice
Goodman and Percy
Adv. Physiol. Educ. 2005;29:75-82.
ABSTRACT
| FULL TEXT
|
